{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:39:16Z","timestamp":1761597556515,"version":"build-2065373602"},"reference-count":11,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T00:00:00Z","timestamp":1415404800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:table-wrap position=\"anchor\">\n\n<jats:table frame=\"hsides\">\n<jats:col\/>\n<jats:tbody>\n<jats:tr>\n<jats:td>Postmarketing Phase IV<\/jats:td>\n<\/jats:tr>\n<\/jats:tbody>\n<\/jats:table>\n\n<\/jats:table-wrap><\/jats:p><jats:p>Patients with active rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) frequently show an atherogenic lipid profile, which has been linked with the inflammatory reaction. Inflammatory cytokines, and particularly tumor necrosis factor\u2010alpha (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1), are implicated in the pathogenesis of both atherosclerosis and <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>, and also involved in the development of the impaired lipid profile detected in active <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>. Although anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 agents have been proven effective in controlling joint damage and systemic inflammation, controversy remains about the effect of these drugs on the lipid profile; therefore, the aim of our study was to investigate the effect of anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 treatment, in combination with disease\u2010modifying anti\u2010rheumatic drugs (<jats:styled-content style=\"fixed-case\">DMARDs<\/jats:styled-content>) and corticosteroid therapy, on the lipid profile of patients with active <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>. Our data suggest that the combination anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1\/<jats:styled-content style=\"fixed-case\">DMARDs<\/jats:styled-content>\/steroids do not significantly interfere with the lipid profile of <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients. However, analysis of clinical response data showed that patients achieving low disease activity or remission seem to have a protective lipid profile, suggesting that better control of inflammation and disease activity can affect lipid metabolism. The available evidence indicates that high inflammation interferes with lipid metabolism, whereas good control of the chronic inflammatory state may positively influence the lipid profile and cardiovascular risk. Low cholesterol levels at baseline could predict a favorable outcome with anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 treatment, but these data need to be confirmed by large prospective studies with long\u2010term follow\u2010up.<\/jats:p>","DOI":"10.1002\/ddr.21203","type":"journal-article","created":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T08:02:04Z","timestamp":1415433724000},"source":"Crossref","is-referenced-by-count":11,"title":["Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti\u2010Tumor Necrosis Factor\u2010Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response"],"prefix":"10.1002","volume":"75","author":[{"given":"Fabio","family":"Cacciapaglia","sequence":"first","affiliation":[{"name":"Internal Medicine Unit and Outpatient Clinic of Rheumatology \u201cN. Melli\u201d Hospital of San Pietro V. co  Brindisi 72027 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Anelli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit University Medical School of Bari  Bari 70124 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit University Medical School of Bari  Bari 70124 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Serafino","sequence":"additional","affiliation":[{"name":"Rheumatology Unit University Medical School of Bari  Bari 70124 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Covelli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit University Medical School of Bari  Bari 70124 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crescenzio","family":"Scioscia","sequence":"additional","affiliation":[{"name":"Rheumatology Unit University Medical School of Bari  Bari 70124 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Rheumatology Unit University Medical School of Bari  Bari 70124 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[{"name":"Rheumatology Unit University Medical School of Bari  Bari 70124 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00017.2013"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161212799504803"},{"key":"e_1_2_7_5_1","first-page":"4","article-title":"Recent advances in the relationship between obesity, inflammation, and insulin resistance","volume":"17","author":"Bastard JP","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802055984"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.168"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.222"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01186-5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R600021-JLR200"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.09.006"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.04.003"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:59:18Z","timestamp":1760345958000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":11,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/ddr.21203"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21203","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"type":"print","value":"0272-4391"},{"type":"electronic","value":"1098-2299"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}